Navigation Links
NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
Date:9/4/2007

dies of NGX-4010.

Dr. Jeffrey Tobias, Chief Medical Officer, commented, "We believe that NGX-4010 has the potential to provide an important therapeutic alternative to patients suffering from postherpetic neuralgia, a frequent, yet difficult to manage, neuropathic pain condition that can affect up to one in five shingles patients. We believe that a significant unmet medical need exists in the treatment of PHN, and that the results from this trial mark a significant step in our goal of providing an effective, peripherally-acting treatment option for this patient population."

Anthony DiTonno, Chief Executive Officer, said, "We believe that the results from this study are a significant validation of our efforts to develop our lead product candidate, NGX-4010, and for NeurogesX. These results represent a key milestone in our NGX-4010 development program. We feel that the consistency of both the magnitude and duration of effect of NGX-4010 is evidence of the potential benefits of this product candidate. With over 1,500 patients in our PHN and painful HIV-distal sensory polyneuropathy (HIV-DSP) clinical studies to date, we believe that we are building a significant body of evidence in support of a potential new drug application (NDA) filing in the second half of 2008."

NGX-4010 is a dermal patch designed to manage peripheral neuropathic pain. This is the second of two successful Phase 3 clinical trials of NGX-4010 for PHN that the Company has completed in the past year. The previously completed Phase 3 trial also demonstrated that a single, 60-minute treatment with NGX- 4010 applied directly to the site of pain may provide pain relief for up to 12 weeks.

In addition to being studied in PHN, NGX-4010 was also studied in a successful Phase 3 clinical trial in painful HIV-DSP and is currently being studied in a second Phase 3 trial for this indication which is currently in excess of 90% enrolled. Top-line results from this ongoing trial are expected in
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" research ... http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging of ... orthopedic instrument industry has seen rapid development ... 3.28 billion yuan in 2006 to 9.85 billion yuan ...
(Date:1/15/2014)... 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has ... - Global Industry Analysis, Size, Share, Growth, Trends And ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... on patients in order to treat dental impairments, for ...
(Date:1/15/2014)... WASHINGTON , Jan. 15, 2014 AARP Foundation today ... support older adults suffering from the severe cold weather that ... are committed to helping those in need; so to support ... dollar-for-dollar contributions up to $250,000, which could mean up to ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... ST. LOUIS, Oct. 25, 2011 HIGHLIGHTS:2011 ... Q3 2011 reported sales increased 11% to ... products and Fine Chemicals ("SAFC") sales growing organically by 4% ... and changes in foreign currency exchange rates contributed an additional ...
... Company (NYSE: LLY ) has updated its full-year 2011 ... company,s Xigris ® product. Lilly expects to incur ... and contractual commitments related to Xigris. The exact amount of the ... in the range of $75.0 million to $95.0 million (pre-tax), or ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13Lilly Provides Update on 2011 Financial Guidance Due to Xigris Withdrawal 2
(Date:7/9/2014)... -- Vasectomy was associated with a small increased risk ... or lethal prostate cancer according to a new study ... found that the association remained even among men who ... lethal cancer cannot be explained by diagnostic bias. It ... to look at the link between vasectomy and prostate ...
(Date:7/9/2014)... captures heretofore hidden ways that cells are regulated, scientists ... breast cancer cells more likely to metastasize. , What,s ... part by blocking two other proteins that are normally ... disease processes could have unexpected ties. , The ... Nature , points to the possibility of new ...
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective ... immunocompromised patients. This is the result of a study ... Center for Women,s Gastrointestinal Medicine at The Women,s Medicine ... online in advance of print in the American ... or C. diff , has increased to epidemic ...
(Date:7/9/2014)... By looking at ... structure and function, personality, life experiences and genetics, researchers can ... binge drinking within the next two years. Impulsivity, hopelessness, sensation-seeking ... events and a family history of drug use contribute to ... child had had a single drink at age 14 was ...
(Date:7/9/2014)... for more than watching World Cup highlights, Brian Williams ... landing in unfortunate positions on railings. A University of ... Online Journal shows that YouTube also allows researchers, ... public on topics of skin cancer and prevention. , ... the future of how we communicate around the world," ...
Breaking Medicine News(10 mins):Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:What drives a child to abuse alcohol? 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2
... Broad Institute of Harvard and MIT have received a ... ways to encourage the human body to replenish the ... by the Juvenile Diabetes Research Foundation (JDRF), the $3M ... fields, genome biology and chemical biology, to address a ...
... NASHUA, N.H., July 21 iCAD, Inc. (Nasdaq:,ICAD), ... announced the completion of its previously announced,agreement to ... medical technology company based in White Plains, NY. ... million in cash and,1,086,957 shares of iCAD common ...
... July 21 Fidelity National,Financial, Inc. (NYSE: ... insurance, claims management services and information services,today announced ... Mexico,Fidelity National Title de Mexico S.A. de C.V. ... been appointed Vice President and General,Manager and Gerardo ...
... July 21 iNutrition, Inc, (http://www.inutrition.com ) ... of Natural Nutrition, Inc, (OTC,Bulletin Board: NTNI) ... an,agreement with actor John O,Hurley ("Seinfeld," "Dancing ... endorser and spokesman for the Companies in,their ...
... melatonin strip ... BOCA RATON, Fla., July 21 TransMedia Group said it ... Sleep, all-natural,sleep aid for people who can,t wait for pills to ... asleep fast and safely. MedGen Inc.,the makers of Snorenz, which has ...
... university aligns with National League of Nursing competencies; helps address ... ... Minneapolis, MN (PRWEB) July 20, 2008 -- Capella University ... has announced a new PhD in Education specialization in Nursing ...
Cached Medicine News:Health News:Broad Institute earns grant to support pathbreaking diabetes study 2Health News:Broad Institute earns grant to support pathbreaking diabetes study 3Health News:iCAD Completes Acquisition of CAD Sciences 2Health News:Fidelity National Financial, Inc. Announces Opening of Fidelity National Title de Mexico S.A. de C.V. 2Health News:Fidelity National Financial, Inc. Announces Opening of Fidelity National Title de Mexico S.A. de C.V. 3Health News:iNutrition Signs John O'Hurley to Launch New Internet Video Campaign 2Health News:Sweet Dreams, Sweet Breath: MedGen Inc. Retains TransMedia Group to Send Media a Wake-Up Call About an All-Natural, Quick New Way to Slumber Land 2Health News:Capella University Launches Online PhD Specialization in Nursing Education 2Health News:Capella University Launches Online PhD Specialization in Nursing Education 3
Suture Cutter, 15 Up Curve...
Portal accessory instrument set. Set also includes a package of 8 mm Guide Wires (.15 cm x 38 cm), and Sterilization Tray....
...
Knot tier...
Medicine Products: